Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

At week 16, 55.9% of the risankizumab group and 5.1% of the apremilast group achieved PASI 90. 75.4% of risankizumab-treated patients vs. 18.4% of apremilast-treated patients achieved sPGA 0/1 by ...

Risankizumab is an interleukin (IL)-23 p19 inhibitor that was approved for the treatment of adults with moderately to severely active Crohn's disease in June 2022, while ustekinumab is an IL-12/23 ...

Risankizumab is used for treating psoriasis especially in moderate-to-severe plaque psoriasis in adult patients.Psoriasis is a skin disorder in which there are red, itchy scaly patches on knees ...

The FDA approved risankizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, in March 2019 for the treatment PsA in adults.

Risankizumab Safe in Older Crohn's Disease Patients — Our expert roundtable discusses the findings of a post-hoc analysis presented at DDW by Greg Laub, Director, Video, MedPage Today June 9, 2023 ...

Risankizumab is approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a humanized ...

AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an ...

Risankizumab was superior to secukinumab at week 52, with 87% of patients achieving PASI 90 vs. 57% achieving PASI 90 (P < .001), respectively. All secondary endpoints supported risankizumab ...

In the risankizumab group, median time to first asthma worsening was 40 days, significantly worse than the 86 days reported for the placebo group (hazard ratio, 1.46; 95% CI, 1.05 – 2.04; P = .03).

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...